Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioma 1Glioblastoma 1Astrocytoma 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Temozolomide 44Radiotherapy 20Magnetic Resonance Spectroscopy 13Irinotecan 13Carboplatin 11Bevacizumab 11Filgrastim 9Surgical Procedures, Operative 7Procarbazine 6sargramostim 5Vincristine 5Imatinib Mesylate 5Etoposide 5Erlotinib Hydrochloride 5Carmustine 5Biopsy 5etoposide phosphate 4Peripheral Blood Stem Cell Transplantation 4Lomustine 4Immunohistochemistry 4Cyclophosphamide 42-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 4temsirolimus 3poly ICLC 3aldesleukin 3Thalidomide 3Surveys and Questionnaires 3Radiation 3Polymerase Chain Reaction 3Gadolinium DTPA 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Oligodendroglioma × regadenoson × Clear all
NCT03971734 2023-10-06

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Terminated
7 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡